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Context:Familialglucocorticoiddeficiency(FGD)isanautosomalrecessivedisorderresultingfrom
resistancetotheactionofACTHontheadrenalcortex.Affectedindividualsaredeficientincortisol
and, if untreated, are likely to succumb to hypoglycemia and/or overwhelming infection. Muta-
tionsoftheACTHreceptor(MC2R)andthemelanocortin2receptoraccessoryprotein(MRAP),FGD
types 1 and 2 respectively, account for approximately 45% of cases.
Objective:Alocusonchromosome8haspreviouslybeenlinkedtothediseaseinthreefamilies,but
no underlying gene defect has to date been identified.
Design:Thestudydesigncomprisedsingle-nucleotidepolymorphismgenotypingandmutationdetection.
Setting: The study was conducted at secondary and tertiary referral centers.
Patients: Eighty probands from families referred for investigation of the genetic cause of FGD
participated in the study.
Interventions: There were no interventions.
Results: Analysis by single-nucleotide polymorphism array of the genotype of one individual with
FGDpreviouslylinkedtochromosome8revealedalargeregionofhomozygosityencompassingthe
steroidogenicacuteregulatoryproteingene,STAR.WeidentifiedhomozygousSTARmutationsin
this patient and his affected siblings. Screening of our total FGD patient cohort revealed homozy-
gous STAR mutations in a further nine individuals from four other families.
Conclusions: Mutations in STAR usually cause lipoid congenital adrenal hyperplasia, a disorder
characterizedbybothgonadalandadrenalsteroiddeficiency.Ourresultsdemonstratethatcertain
mutations in STAR (R192C and the previously reported R188C) can present with a phenotype
indistinguishable from that seen in FGD. (J Clin Endocrinol Metab 94: 3865–3871, 2009)
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amilial glucocorticoid deficiency (FGD), or hereditary
unresponsivenesstoACTH(onlineMendelianinher-
itance in man no. 202200), is an autosomal recessive dis-
order resulting from resistance to the action of ACTH to
stimulateglucocorticoidproductionintheadrenalcortex.
Affected individuals are deficient in cortisol and, if un-
treated, are likely to succumb to hypoglycemia or over-
whelminginfectionininfancyorchildhood.Mutationsof
the ACTH receptor (melanocortin 2 receptor, MC2R)
(1–3) or the melanocortin 2 receptor accessory protein
(MRAP) (3, 4) cause FGD types 1 and 2, respectively, and
account for approximately 45% of all cases.
In an attempt to identify further genetic loci, we pre-
viously conducted a genome-wide linkage study using mi-
crosatellite markers. This provided evidence for a further
locus on chromosome 8 (8q 12.1 to 8q21.2), in three (of
14) families (5). This locus was 26 Mb in size and con-
tained more than 150 known or predicted genes, none of
whichwereanobviouscandidateforFGD.Themultipoint
limit of detection score in the index family was 3.01, and
limit of detection scores of 1.28 and 1.20 were obtained
for two other families, but linkage to this locus was ex-
cludedinafurtherfivefamilies,indicatingthatatleasttwo
more gene defects were responsible for FGD (5).
We reanalyzed this region by single-nucleotide poly-
morphism (SNP) genotyping in one of the three original
8q-linkedfamiliesintheexpectationofnarrowingthesize
of the critical region and perhaps enabling a focused se-
quencing strategy. As we describe, it was the opposite ef-
fectofenlargingthecriticalregionthatenabledustoiden-
tify a strong candidate gene, the steroidogenic acute
regulatory protein (StAR). More than 40 mutations in
STARhavepreviouslybeendescribed(6–13),mostlycon-
centrated in the C-terminal half of the protein encoded by
exons 5, 6, and 7 and causing lipoid congenital adrenal
hyperplasia(LCAH;onlineMendelianinheritanceinman
no. 201701). Patients with this condition usually present
withinthefirstfewmonthsoflifewithhyperpigmentation
andhighACTHandreninlevelscoupledwithlowcortisol
and aldosterone levels. In patients with a 46,XY karyo-
type,theabsenceoffetaltestosterone/dihydrotestosterone
production may lead to failure of androgenization and a
femalephenotype.Affectedfemalesundergoanormalpu-
berty but have progressive hypergonadotropic hypogo-
nadism (14, 15).
Examples of partial loss-of-function mutations of
STAR, with a later onset have also been reported; the first
such case described a Korean girl with mild disease who
survived until 1 yr of age without hormonal replacement
(16). Analysis of STAR revealed a splice donor site mu-
tation, which resulted in the inclusion of intron 2 in most
RNAtranscripts,leadingtoaframeshiftandtruncationof
the protein, but the retention of some normally spliced
transcriptandhenceStARproteinpresumablyallowedthe
development of a less severe phenotype. In 2006 Baker et
al. (17) described FGD-like phenotypes in three patients
with mutations in adjacent codons V187M, R188C.
Structural modeling of these two residues, which are
within the cholesterol-binding pocket of StAR, suggested
that the R188C mutation would prevent the formation of
a salt bridge normally present between residues E169 and
R188 but result in a new weaker bond between residues
T167andR188thatmaypreservetheshapeofthebinding
pocket well enough to transport cholesterol. Functional
analysisofbothV187MandR188Cmutantsrevealedthat
they retained greater than 20% cholesterol binding activ-
ity(17).Thisresidualactivitymaybethereasonthatthese
patients presented after the age of 2 yr with cortisol defi-
ciencyandmildhyperreninemia,thusresemblingpatients
with FGD.
Patients and Methods
Probands from 80 families referred to us with a possible diag-
nosis of FGD were included in this study and their STAR genes
sequenced. This cohort included patients from one family pre-
viously described by us (family 14 in Ref. 5). Criteria for inclu-
sion in this patient cohort were low or absent cortisol produc-
tion; high ACTH levels; and no report of severe hyponatremia,
hyperreninemia, or aldosterone deficiency. Adrenal autoanti-
bodieswerenegative,circulating17-hydroxyprogesteroneand
very long-chain fatty acids (in males) were within normal limits,
and there was no clinical evidence of alacrima or achalasia or
otherfeaturessuggestiveoftripleAsyndrome.InallcasesMC2R
and MRAP mutations had been excluded. This study was ap-
proved by the local research ethics committee, and individuals and/or
their parents gave written informed consent to participate.
SNP genotype analysis
Forthewhole-genomescan,theGeneChipmapping10Karray
Xba142(Affymetrix,SantaClara,CA)wasusedinaccordancewith
the manufacturer’s guidelines. This version of the Mapping 10 K
array comprises a total of 10,024 SNPs with a mean intermarker
distance of 258 kb, equivalent to 0.36 cM. SNP genotypes were
scanned for regions of homozygosity using IBDFinder from the
Centre for Autozygosity (http://autozygosity.org).
Genetic analysis
Genomic DNA was extracted from peripheral blood leuko-
cytes,andeachexonofSTARincludingintronicboundarieswas
amplifiedbyPCRusingspecificprimers(supplementalTableS1,
publishedassupplementaldataonTheEndocrineSociety’sJour-
nals Online web site at http://jcem.endojournals.org). Cycling
conditions were 95 C for 5 min (one cycle); 95 C for 30 sec, 55
C for 30 sec, and 72 C for 30 sec (30 cycles); and 72 C for 5 min.
PCRproductswerevisualizedon1%agarosegelandsequenced
using the ABI Prism Big Dye sequencing kit and an ABI 3700
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Results
Genotype and sequencing analysis
Whole genome SNP analysis was undertaken on DNA
from the proband of family 1 Fig. 1; individual II:5 (14:3
from Ref. 5). Analysis of the genotype for this individual
displayed a region of homozygosity on chromosome 8
from SNP rs1405535 to SNP rs372976 (25.1–82.6 Mb).
This region encompasses the centromere and part of the
shortarmofchromosome8andissignificantlylargerthan
the region of homozygosity previously described (57.2–
83.4 Mb) (Fig. 2).
Thisrevisedcriticalintervalextendedtoincludethelocus
for the STAR gene at 38.1 Mb (chromosome 8p12). In view
of the key role of StAR in early steroidogenesis, it makes a
very plausible candidate gene for FGD, and thus, the gene
was sequenced, revealing a novel homozygous mutation
R192C in the four affected individuals in family 1 (Fig. 1).
Both parents were heterozygous for this mutation.
To ascertain whether there were other StAR mutations
presenting as FGD, screening of our total FGD patient
cohort was undertaken. Sequencing of individuals from a
further 79 families revealed the presence of STAR muta-
tions as described below (Fig. 1). The parents in these
families were heterozygous.
The clinical histories of the affected individuals are as
follows.
Family 1
The male proband (II:5) in family I presented at 5 yr of
age with pigmentation and episodes of diarrhea and vom-
iting. His parents are first cousins. In the absence of evi-
denceofmineralocorticoiddeficiency,hewastreatedwith
hydrocortisone replacement alone (10 mg twice daily)
(Table 1). Three older sisters (II:1, II:2, and II:3) were
screened and found to be similarly affected and thus also
treatedwiththesamedoseofglucocorticoid.Theproband
wasreassessedat25yrofage,andisolatedglucocorticoid
deficiency with elevated ACTH was confirmed. At this
time testosterone was 550 ng per 100 ml, LH was 6.8
IU/ml, and FSH was 2.2 IU/ml. At age 36 yr, he was in-
vestigated for infertility and was found to have a testos-
terone level of 280 ng per 100 ml, with LH 12 IU/ml and
FSH 24 IU/ml. A testicular biopsy at this time revealed
partial atrophy, with interstitial fibrosis. Many Reinke
crystalloids were seen (Fig. 3), confirming positive iden-
tification of Leydig cells. Reinke crystalloids are fre-
quently difficult to see in testicular biopsies, and their
prominentpresenceinthiscaseisthereforeinterestingand
may reflect Leydig cell hyperplasia. The remaining semi-
niferoustubulesshowedgreatlyreducedspermatogenesis,
but occasional spermatozoa as well as many spermato-
cytes were identified. The Sertoli cells were unusual and
showed a frequently vacuolated appearance, occasionally
formingasignetring-typeappearance.Theaffectedsisters
have had an uncomplicated menstrual history (without
pregnancies) and two are now postmenopausal at ages 49
and50yr,whereasthethirdispremenopausalatage46yr.
GeneticanalysisrevealedahomozygousR192Cmutation
of STAR in all affected individuals.
Family 2
The female proband (III:5) was first seen at the age of
2 yr because of pigmentation and a previous diagnosis in
Family 1: R192C  Family 2: R188C 
Family 4: R188C 
II:1   II:2    II:3    II:4     II:5 
II:1     II:2     II:3     II:4
Family 3: R188C 
II:1      II:2 
Family 5: R188C 
II:1     II:2    II:3
III:1    III:2   III:3  III:4   III:5    III:6 
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
I:1      I:2 I:1      I:2
I:1      I:2 I:1      I:2 I:1      I:2
FIG. 1. Pedigrees of families 1–5 with STAR mutations. All affected
individuals (black symbols) were homozygous for the indicated
mutations, unaffected parents and siblings (where characterized) were
all heterozygous (half-filled symbols), uncharacterized individuals are
represented by gray symbols, and probands are indicated by arrows.
FIG. 2. Ideogram of chromosome 8 indicating the position of STAR,
the original interval (broken arrow) mapped by microsatellites and
limited by markers D8S285 and D8S1697 (57.2–83.4 Mb) and the
region mapped by SNPs (solid arrow), extending from SNP rs1405535
to SNP rs372976 (25.1–82.6 Mb).
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investigation showed glucocorticoid deficiency without
mineralocorticoid deficiency, and replacement with hy-
drocortisone alone was successful (Table 1). Their par-
ents, from Newfoundland, are unrelated, but both had
ancestorsfromSheffield,UK.Anotherbrother(III:1),who
died at the age of 3 yr, was also suspected to be affected.
In the previous generation, one paternal uncle (II:2) was
reported to be dark complexioned and another (II:4) died
aged 2–3 yr with suspected Addison’s disease. The pro-
bandremainswellandhastwochildren,whereasherolder
brother (III:2) has one child. Genetic analysis revealed a
homozygous R188C mutation of STAR in both affected
individuals and their uncle (II:2), who has four children
andwhowasbothundiagnosedanduntreateduntilhewas
58 yr. Family members III:3, III:4, and III:6 and their par-
ents were heterozygous for the mutation.
Family 3
Two brothers (II:1 and II:2), with nonconsanguineous
parents, had become pigmented after the second year of
life. The male proband (II:1) was well until age 6 yr when
he had an episode of diarrhea and vomiting, resulting in
coma. A diagnosis of possible Addison’s disease was
made. Both children were treated with cortisone acetate
alone(15mg/m
2  d),didnothavesaltcraving,andhadno
prior history of adrenal disorders. The endocrine findings
were reassessed at age 15 yr (II:1) and 12 yr (II:2) and
glucocorticoid deficiency, with cortisol levels of 70 and
140 nmol/liter for individuals II:1 and II:2, respectively,
but with normal mineralocorticoid function was con-
firmed. Both boys underwent normal pubertal develop-
ment: II:1 began his puberty age 12 yr and at 15 yr he had
Tanner V pubic hair and 20 ml testes, and sibling II:2 had
Tanner I pubic hair and 6 ml testes bilaterally at 12 yr.
GeneticanalysisrevealedahomozygousR188Cmutation
of STAR in both affected individuals and their parents
were heterozygotes.
Family 4
The female proband (II:1) presented at 18 months of
agewithhyperpigmentationofthelips;twoyoungermale
siblings(II:2,II:3)werediagnosedwithglucocorticoidde-
ficiency, with low cortisol and high ACTH levels, on
screening before 1 yr of age because of prior diagnosis of
their sister. Their parents are consanguineous and come
from Jordan. All three affected children had high ACTH
levels (ranging from 264 to 592 pmol/liter) and low cor-
tisol levels (30 nmol/liter for all three), with no clinical
evidenceofmineralocorticoiddeficiencyandarecurrently
onhydrocortisonereplacement(doses9.3–10.1mg/m
2  d)
alone (at ages 13, 11, and 8 yr). Sibling II:2 had bilateral
cryptorchidism. Genetic analysis revealed a homozygous
R188C mutation of STAR in all affected individuals.
FIG. 3. Testis histology in patient I:5 showing reduced spermatogenesis
and vacuolation of Sertoli cells (arrowed) (A) and Leydig cells with many
Reinke crystalloids (arrowed) on a background of atrophy (B).
TABLE 1. Clinical and biochemical characteristics of patients with FGD type 3
Family 1
R192C
Family 2
R188C
Family 3
R188C
Family 4
R188C
Family 5
R188C
Individual II:5 III:5 II:1 II:1 II:1
S e x MF MF M
Age at diagnosis (yr) 5 2 7 1.5 3
ACTH (NR 4–22 pmol/liter) 50 ND 327 331 275
Cortisol (NR 150 nmol/liter) 17 Undetectable 70–140 30 43
ALDO (NR 111–860 pmol/liter) 33 32 108 ND 165
PRA (NR 0.76–3.2 nmol/liter  h) 4.48 ND 0.88 10 2.72
LH (NR 4–12 mIU/ml in male) 21.9 ND ND ND 15.7
FSH (NR 4–10 mIU/ml in male) 50.4 ND ND ND 9.5
Country of origin Lebanon Newfoundland, Canada Newfoundland, Canada Jordan India
ALDO, Aldosterone; ND; not determined; NR, normal range; PRA, plasma renin activity.
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The male proband (II:1), the first of three sons of non-
consanguineousparents,hadbeenrepeatedlyunwellfrom
birth and was diagnosed with adrenal insufficiency at age
3 yr. Hyponatremia was documented at presentation; the
patient was started on combined hydrocortisone and
fludrocortisone replacement, but mineralocorticoid re-
placementwasstoppedatage10yrwithoutproblems.He
underwent repair of a glandular hypospadias at age 4 yr.
Pubertal development was normal. Endocrine reassess-
mentat18yrrevealedACTHgreaterthan1250ng/mland
a low baseline cortisol (43 nmol/liter) with inappropriate
response to cosyntropin (268 nmol/liter). Plasma renin
activity and serum aldosterone were normal. Because of
complaints about lack of energy and increasing demands
for hydrocortisone, he was initiated on fludrocortisone at
age 26 yr, which yielded considerable clinical improvement.
Assessment at age 28 yr revealed normal testosterone (11.8
nmol/liter, normal range 7.0–27.0) but up-regulated LH
(15.7 IU/liter, normal range 1.7–8.6), indicating compen-
sated hypogonadism. Testicular volume, sperm count, and
motility testing results were entirely normal. Computed to-
mography imaging revealed markedly hypoplastic adrenals
with spotty calcifications, suggestive of cirrhotic transfor-
mation.GeneticanalysisrevealedahomozygousR188Cmu-
tation of STAR in this patient.
Discussion
FGD is a rare autosomal recessive syndrome that repre-
sents a relatively pure model of hormone resistance with
an absence of associated factors. As such it provides an
excellent model for understanding the early molecular
events in ACTH action at its primary target site, the ad-
renalcortex.Thus,thediscoverythatmutationsinMC2R
wereassociatedwithFGDprovidedstrongsupportingev-
idence that this receptor was the primary functional re-
ceptor for ACTH (1, 2). The subsequent discovery that
mutations in MRAP were associated with FGD (4) re-
vealed a fundamental role for this accessory protein in
ACTHsignaling.Mutationsinthesegenesaccountforless
thanhalfofallcasesofFGD,andthereappeartobeseveral
further loci to be discovered, each of which may reveal
important aspects of early ACTH action. There is some
evidenceofphenotypicvariationwithinthisgroupofFGD
patients of unknown cause, exemplified by the recent re-
port of FGD in the Irish Traveler population (18).
A genetic locus for FGD on chromosome 8 was iden-
tified several years ago (5), but it was only on reexamina-
tion of the data using alternative methodology that it be-
camecleartheoriginalcriticalintervalonchromosome8q
had been significantly underestimated. This probably re-
flects a miscalled microsatellite marker (D8S285), a not-
unknown difficulty with this technique. Once the size of
the true locus was clear, the possibility that STAR might
be the causative gene seemed highly plausible.
StAR plays a critical early role in adrenal and gonadal
steroidogenesis in facilitating the transport of cholesterol
across the inner mitochondrial membrane, after which it
is further metabolized along the steroidogenic pathways.
However, up to 14% of a maximal StAR-induced level of
steroidogenesis can persist in the absence of StAR (19).
Mutations in STAR usually result in LCAH (online Men-
delian inheritance in man no. 201701), a severe disorder
characterized by both gonadal and adrenal steroid insuf-
ficiency. Miller’s two-hit model (20) explains the clinical
manifestations of LCAH. It suggests that, over time, lipid
deposition in steroidogenic cells gradually destroys their
function. Hence, the fetal testis is affected early in gesta-
tion due to stimulation with chorionic gonadotropin, and
the fetal zone of the adrenal gland responsible for dehy-
droepiandrosterone secretion is similarly affected. Mean-
while, the definitive zone of the fetal adrenal, which de-
velopsintotheadrenalzonaeglomerulosaandfasciculata,
is relatively preserved until birth but quickly accumulates
cholesterol esters after birth and is destroyed. The fetal and
childhood ovary, on the other hand, does not build up lipid
depositsuntilafterpubertywhenLHandFSHstimulateste-
roidogenesis (14, 15).
Our results highlight the fact that patients with par-
tially inactivating mutations in STAR such as R188C and
R192Ccanpresentaclinicalphenotypethatiscompatible
with a diagnosis of FGD. Such cases are more common
thanpreviouslyrecognizedandaccountforabout10%of
our FGD cohort. The relative preservation of mineralo-
corticoid production probably reflects the lower produc-
tion rate of aldosterone compared with cortisol which al-
lows the adrenal zona glomerulosa to escape damage by
lipid deposition. Furthermore, gonadal function allowed
for normal male and female pubertal development, and
interestingly,affectedsiblingsinfamily2,brotherIII:4his
sister III:7 and their affected uncle II:1, all have children.
Theadultphenotype,however,isindicativeofpotentially
compromised fertility in a number of patients. Although
thethreeaffectedwomeninfamily1reportedregularmen-
strual cycles, none of them reported a pregnancy. Their
brother,patientII:5,didnotdiscoverhisgonadaldysfunc-
tionandazoospermiauntil36yrofage.Atesticularbiopsy
in this patient shows reduced spermatogenesis and evi-
dence of Leydig cell atrophy but no evidence of lipid dep-
osition in steroidogenic cells. This phenotype is distinct
from that reported by Aya et al. (21), who described the
testicularhistopathologyintwomalepatientswithLCAH
whounderwentorchiectomyatages7and12yr,revealing
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droplets.Similarly,thepatientII:1infamily5hadnormal
appearance of testicular tissue at ultrasound, and he cur-
rently has normal fertility potential as documented by
sperm count and motility testing. However, endocrine as-
sessment suggests compensated primary hypogonadism,
anditispossiblethatat10yronward,thismightprogress
to manifest hypogonadism and azoospermia. Of note,
both his adrenals were hypoplastic with calcifications, re-
sembling a cirrhotic end stage of previous fat deposition,
similar to imaging changes observed during progression
from steatosis hepatis to liver cirrhosis.
It would be interesting to compare the adrenal histol-
ogy of these patients in contrast to those with MC2R mu-
tationsandMRAPmutations.Inthelattercases,therewill
be no action of ACTH on the zona fasciculata and reticu-
laris cells, resulting in marked atrophy of these zones. In
our patients with STAR mutations, it is probable that the
nonsteroidogenic actions of ACTH will be preserved, at
least for the early period of life, and adrenal atrophy may
be absent.
In conclusion, it is clear that STAR mutations present
with a spectrum of phenotypes. At one end of this spec-
trum is classic lipoid adrenal hyperplasia, seen in the ma-
jority of patients with STAR mutations, but it extends
through a phenotype of adrenal dysfunction presenting
like FGD with or without disordered sex development
(DSD) and can even result in a phenotype that is so mild
itremainsunrecognized,asexemplifiedbyindividualII:2,
whoremainedundiagnosedanduntreateduntiltheageof
58 yr. There are some important clinical implications of
these findings. First, it is not adequate to make a clinical
diagnosis of FGD and then to replace the patient with
hydrocortisone with little or no follow-up. Ideally a ge-
netic diagnosis should be made, but when this is not pos-
sible or when a genetic defect cannot be identified, the
patients should remain under follow-up because their dis-
ordermayevolve.Second,wemustconsidertheclosecon-
nection between gonad and adrenal during human fetal
development when investigating individuals with appar-
ently isolated adrenal failure and apparently isolated
DSD, respectively, because the obvious manifesting phe-
notypemightnotrevealthewholestory.Disordersaffect-
ing both adrenal and gonadal development may present
withisolatedadrenalfailure,aspreviouslyshownfordos-
age-sensitive sex reversal-adrenal hypoplasia congenita
critical region on the X chromosome, gene 1 mutations
(22), or with DSD only, as reported for steroidogenic fac-
tor 1 mutations (23). The five probands we describe here
clearly presented clinically as FGD; however, if the full
clinical picture had been taken into account for the pro-
band in family 5, who underwent a hypospadias repair,
and the proband in family 4, whose brother had cryp-
torchidism,thenmutationsinSTARmighthavebeensus-
pected sooner. In the other three families, no DSD was
apparent to raise the suspicion of a defect in STAR.I n
clinical practice it will be important to clearly label these
patientsassufferingfromnonclassicLCAHtoensurethat
both adrenal and gonadal function is appropriately mon-
itoredandprogressionofphenotypicexpressioniscaught
early.
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